西咪匹韦治疗基因1型丙型肝炎的有效性和安全性的Meta分析

发布时间：2018-04-14 12:02

本文选题：西咪匹韦 + 基因型丙肝　；参考：《中国医院药学杂志》2017年19期

【摘要】：目的:评价西咪匹韦治疗基因1型丙型肝炎的疗效和安全性。方法:检索EMBASE、PubMed、The Cochrane Central Register of Controlled Trials、clinicaltrials.gov、CNKI全文数据库、万方数据库中关于西咪匹韦治疗基因1型丙型肝炎的疗效和安全性的随机对照试验,检索起始日期为2000年1月1日,截止时间为2016年8月8日。采用RevMan5.3对纳入的研究进行Meta分析。结果:共7项研究符合纳入标准入选本Meta分析,共纳入2 301例患者。分析结果显示西咪匹韦快速病毒学应答(RVR)、持续早期病毒应答(SVR12)、持续病毒学应答(SVR24)等获得率均明显高于对照组(P0.000 1),病毒复发率明显低于对照组(P0.000 1);100 mg组西咪匹韦RVR,SVR12,SVR24,病毒复发率等指标明显优于对照组(P0.001),而150 mg组除了SVR24与对照组对比,差异无统计学意义外(P0.05),其余指标均优于对照组(P0.001)。西咪匹韦组一般不良反应发生率与对照组相比,差异无统计学意义(P0.05),与临床治疗相关的不良反应中除了对光敏感发生率高于对照组,其余不良反应如皮疹、瘙痒、中性粒细胞减少、贫血事件发生率均与对照组对比无统计学差异(P0.05)。结论:西咪匹韦用于治疗基因1型丙肝具有较好疗效及安全性。100 mg西咪匹韦较150 mg西咪匹韦用于治疗基因1型丙肝疗效更佳。
[Abstract]:Objective: to evaluate the efficacy and safety of cimepivir in the treatment of hepatitis C type 1.Methods: the Cochrane Central Register of Controlled trialtrials.gova CNKI full-text database was searched. A randomized controlled trial on the efficacy and safety of cimepivir in the treatment of hepatitis C type 1 was conducted on January 1, 2000.The deadline is August 8, 2016.RevMan5.3 was used to analyze the included study by Meta.Results: a total of 7 studies were included in this Meta analysis according to the inclusion criteria, and a total of 2 301 patients were included.The results showed that the obtaining rates of cimepivir rapid virological response (RVRV), persistent early virus response (SVR12) and persistent virological response (CDVR) were significantly higher than those of control group (P 0.000 1), and the relapse rate of cimepivir was significantly lower than that of control group (P 0.000 1 / 100 mg), while that of cimepivir RVRSVR12SVR24 in control group was significantly lower than that in control group.The relapse rate of the virus was significantly better than that of the control group (P 0.001), while the 150mg group was compared with the control group in addition to SVR24.The difference was not statistically significant (P 0.05), and the other indexes were better than that of the control group (P 0.001).There was no significant difference in the incidence of general adverse reactions between cimepivir group and control group (P 0.05). The incidence of light sensitivity in cimepivir group was higher than that in control group, but other adverse reactions such as rash, pruritus, and pruritus were also found in cimepivir group.The incidence of neutropenia and anemia events were not significantly different from those of the control group (P 0.05).Conclusion: cimepivir has better efficacy and safety in the treatment of Hepatitis C type 1 than cimepivir 150 mg in the treatment of Hepatitis C 1, and the safety of cimepivir is better than that of cimepivir in the treatment of Hepatitis C.
【作者单位】：华中科技大学同济医学院附属同济医院药学部;中国科学院昆明植物研究所;
【基金】：国家自然科学基金青年基金(编号:81405030)
【分类号】：R512.63

【相似文献】